Source - SMW
Hikma Pharmaceuticals has revised its full year expectations for its generics business but continues to expect full year revenue to be around $2.0bn in constant currency.

The group said its injectables and branded businesses were delivering a good performance but like many of its competitors, it was  experiencing challenging conditions in the US generics market.

At 8:13am: (LON:HIK) Hikma Pharmaceuticals PLC share price was -77.25p at 963.75p